CYCN · Insider Trading
Cyclerion Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by CYCN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-18 | Regina Margaret Graul | See Remarks | MIXED | +7,220 | −$2 |
| 2026-08-18 | Rhonda M. Chicko | Chief Financial Officer | M | +25,000 | +$58.88K |
| 2026-07-20 | Peter M Hecht | Director | C | +351,037 | — |
| 2025-08-11 | Rhonda M. Chicko | Chief Financial Officer | A | +25,000 deriv. | — |
| 2025-03-27 | Michael J Higgins | Director | A | +9,090 | +$25.00K |
| 2025-03-27 | Peter M Hecht | Director | A | +181,818 | +$500.00K |
| 2024-11-25 | Slate Path Capital LP | 10%+ Owner | Sell | −357,880 | −$555.11K |
| 2024-08-07 | Regina Margaret Graul | See Remarks | A | +55,849 deriv. | — |
| 2024-01-26 | Peter M Hecht | Director | A | +15,000 | — |
| 2024-01-26 | Regina Margaret Graul | President | A | +50,000 | — |
| 2023-12-04 | Errol B Desouza | Director | A | +50,000 | — |
| 2023-12-04 | Steven Hyman | Director | A | +20,000 | — |
| 2023-12-04 | Peter M Hecht | Director | A | +35,000 | — |
| 2023-12-04 | Terrance McGuire | Director | A | +5,000 | — |
| 2023-08-11 | Terrance McGuire | Director | Sell | −8 | −$27 |
| 2023-05-22 | Peter M Hecht | Chief Executive Officer | A | +225,000 | +$1.95M |
| 2022-07-27 | Steven Hyman | Director | A | +57,753 deriv. | — |
| 2022-07-26 | Steven Hyman | Director | A | +57,753 deriv. | — |
| 2022-06-16 | George H Conrades | Director | A | +20,000 deriv. | — |
| 2022-06-16 | Terrance McGuire | Director | A | +20,000 deriv. | — |
| 2022-06-16 | Ole Isacson | Director | A | +20,000 deriv. | — |
| 2022-06-16 | Errol B Desouza | Director | A | +20,000 deriv. | — |
| 2022-06-16 | Michael Mendelsohn | Director | A | +20,000 deriv. | — |
| 2022-06-16 | Stephanie Lovell | Director | A | +20,000 deriv. | — |
| 2022-06-16 | Marsha Fanucci | Director | A | +20,000 deriv. | — |
| 2022-01-24 | Peter M Hecht | Chief Executive Officer | A | +482,950 deriv. | — |
| 2022-01-24 | Cheryl Gault | Chief Operating Officer | A | +135,000 deriv. | — |
| 2022-01-24 | Anjeza Gjino | Chief Financial Officer | A | +135,000 deriv. | — |
| 2022-01-24 | Andreas Busch | Chief Scientific Officer | A | +135,000 deriv. | — |
| 2021-12-10 | Andreas Busch | Chief Scientific Officer | A | +75,000 deriv. | — |
| 2021-12-10 | Anjeza Gjino | Chief Financial Officer | A | +100,000 deriv. | — |
| 2021-12-10 | Cheryl Gault | Chief Operating Officer | A | +100,000 deriv. | — |
| 2021-06-28 | Marsha Fanucci | Director | A | +10,000 deriv. | — |
| 2021-06-28 | Errol B Desouza | Director | A | +10,000 deriv. | — |
| 2021-06-28 | Ole Isacson | Director | A | +10,000 deriv. | — |
| 2021-06-28 | Stephanie Lovell | Director | A | +10,000 deriv. | — |
| 2021-06-28 | Terrance McGuire | Director | A | +10,000 deriv. | — |
| 2021-06-28 | Kevin Churchwell | Director | A | +10,000 deriv. | — |
| 2021-06-28 | Michael Mendelsohn | Director | A | +10,000 deriv. | — |
| 2021-06-28 | George H Conrades | Director | A | +10,000 deriv. | — |
| 2021-06-07 | Peter M Hecht | Chief Executive Officer | Buy | +823,170 | +$2.70M |
| 2021-06-07 | Terrance McGuire | Director | Buy | +96,153 | +$300.00K |
| 2021-06-07 | Slate Path Capital LP | 10%+ Owner | Buy | +961,538 | +$3.00M |
| 2021-05-10 | Peter M Hecht | Chief Executive Officer | Buy | +302,000 | +$733.86K |
| 2021-05-06 | Peter M Hecht | Chief Executive Officer | Buy | +698,001 | +$1.69M |
| 2021-03-01 | Anjeza Gjino | Chief Financial Officer | Sell | −1,824 | −$7.30K |
| 2021-03-01 | Christopher I Wright | Chief Medical Officer | Sell | −2,637 | −$10.52K |
| 2020-12-30 | Mark G Currie | President and CSO | Sell | −20,107 | −$60.52K |
| 2020-11-12 | Andreas Busch | Chief Innovation Officer | Buy | +125,000 | +$316.25K |
| 2020-11-10 | William Huyett | Chief Financial Officer | Sell | −3,827 | −$9.64K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Peter M Hecht | Chief Executive Officer | 130,037 | $3.06M |
| Regina Margaret Graul | See Remarks | 22,307 | $524.66K |
| Michael J Higgins | Director | 4,391 | $103.28K |
| Rhonda M. Chicko | Chief Financial Officer | 3,574 | $84.06K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CYCN quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.